ArticleFrontiers in cardiovascular medicine2025
Usability of CHA
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacological cardioversion (PCV) is one of the therapeutic options within rhythm control strategies for atrial fibrillation (AF). Data on clinical determinants influencing its effectiveness and safety in real-world settings remain limited. Methods: This study is a sub-analysis of the multicenter Cardioversion with Intravenous Antazoline in Atrial Fibrillation II (CANT II) registry. The registry retrospectively included consecutive patients with recent-onset AF undergoing urgent PCV in six Polish centers between 2019 and 2020. We analyzed 931 patients stratified according to CHA₂DS₂-VASc score: Group I (0-1 points; Results: The median age was 69 years, 48% were men, and the median CHA₂DS₂-VASc score was 3. Antazoline was used in 59% of patients, amiodarone in 53%, and propafenone in 19%. Sinus rhythm was restored in 69%, 70%, and 64% of patients in Groups I, II, and III, respectively ( Conclusions: In this retrospective sub-analysis of the CANT II registry, success of pharmacological cardioversion of AF is not associated with number of comorbidities as assessed by the CHA2DS2VASc score. PCV remains a feasible and generally safe option in emergency and cardiology department practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.